

Correction: *MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy*

Wang J, Shang Z, Wang J, *et al.* MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. *J Immunother Cancer* 2021;9:e002029. doi:10.1136/jitc-2020-002029

In the original published article, the funding statement was incomplete. The “(No. 8170211 to MX)” lost a number.

The correct funding statement is: This work was supported by the National Natural Science Foundation of China (No. 81 770 211 to MX) and the National Natural Science Foundation of China (No.81830008 to JZ).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

J Immunother Cancer 2022;10:e002029corr1. doi:10.1136/jitc-2020-002029corr1

